A report released today by UBS about Neos Therapeutics (US:NEOS) bumps down the target price to $8.00
- Updated: March 20, 2017
Reporting a potential upside of 0.08%, UBS bumped down the target of Neos Therapeutics (US:NEOS) to $8.00
Yesterday Neos Therapeutics (US:NEOS) traded -3.95% lower at $7.40. The company’s 50-day moving average is $6.03 and its 200-day moving average is $6.56. The last closing price is up 11.24% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 657,823 shares of the stock were exchanged, up from an average trading volume of 309,570
See Chart Below
Neos Therapeutics has a 52 week low of $4.85 and a 52 week high of $11.50 Neos Therapeutics’s market capitalization is currently $0.
Also covering Neos Therapeutics's price target, a total of 4 equity analysts have released a ratings update on NEOS. The one year target is $22.50 with zero equity analysts rating the company a strong buy, zero firms rating the stock a buy, 0 firms rating the stock a hold, zero brokerages rating the company a underperform, and lastly zero brokerages rating the stock a sell.
Brief Synopsis On Neos Therapeutics (US:NEOS)
Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.